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Myeloid and lymphoid malignancies are postulated to have dis-tinct pathogenic mechanisms. The recent observation thatpatients with a myeloproliferative neoplasm have an increased
risk of developing lymphoproliferative malignancies has challenged this
assumption. We collected a nationwide cohort of patients with both
malignancies. Patients diagnosed between 1990 and 2015 were identified
through the national Danish Pathology Registry. We identified 599
patients with a myeloproliferative neoplasm and a concomitant or sub-
sequent diagnosis of lymphoma. Histopathological review of the diag-
nostic samples from each patient led to a final cohort of 97 individuals
with confirmed dual diagnoses of myeloproliferative neoplasm and lym-
phoma. The age range at diagnosis of these individuals was 19-94 years
(median: 71 years). To avoid the inclusion of cases of therapy-induced
myeloproliferative neoplasm occurring in patients previously treated for
lymphoma, only patients with myeloproliferative neoplasm diagnosed
unequivocally before the development of lymphoma were included. The
average time interval between the diagnoses of the two malignancies
was 1.5 years. In the majority of patients (90%) both diagnoses were
established within 5 years of each other. Among the lymphoma entities,
the frequency of peripheral T-cell lymphomas was markedly increased.
Interestingly, all but one of the T-cell lymphomas were of angioim-
munoblastic type. These findings suggest that a myeloproliferative neo-
plasm and lymphoproliferative malignancy developing in the same
patient may have common pathogenic events, possibly already at the
progenitor level. We believe that the molecular characterization of the
newly developed biorepository will help to highlight the mechanisms
driving the genesis and clonal evolution of these hematopoietic malig-
nancies. 
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ABSTRACT
Introduction
The diagnosis of multiple clonal hematologic neoplasms
in the same patient is considered to be rare. Furthermore,
when it does occur, it is unclear whether the individual
disorders are pathogenetically related, e.i., sharing com-
mon driver mutations, or whether they simply reflect
independently developed random events. 
Studies of tumor DNA from patients with angioim-
munoblastic T-cell lymphoma (AITL) have identified
genomic changes which can be detected in the early
hematopoietic stem cell precursors.1–5 These alterations
include changes in IDH2, TET2, and DNMT3A, and are
commonly seen in myeloid malignancies. Acquired
somatic mutation in the Janus kinase 2 (JAK2) gene plays
an essential role in the development of myeloproliferative
neoplasms (MPN). Notably, this mutation has also been
detected in some lymphoid malignancies (LM).6,7 These
findings have prompted the hypothesis that some genom-
ic changes in early hematopoietic stem cell precursors
may predispose to and could drive the development of
both MPN and LM. 
MPN are clonal hematopoietic stem cell disorders char-
acterized by proliferation of one or more of the myeloid-
derived cell lineages. They include essential thrombo-
cythemia (ET), polycythemia vera (PV), primary myelofi-
brosis (PMF), chronic myeloid leukemia (CML) and MPN-
unclassifiable (MPN-U).8 According to the database of can-
cer statistics for Nordic countries (NORDCAN; www-
dep.iarc.fr/NORDCAN/English/frame.asp), the age-adjusted
incidence rate of CML in Denmark is 0.95/100,000 and
that for the other chronic myeloproliferative entities (PV,
ET, PMF, MPN-U; taken as one group) 4.05/100,000. In
general, MPN are slowly progressing diseases which are,
however, capable of transformation to severe bone mar-
row failure or acute leukemia.8 Recent epidemiological
studies have shown an increased risk of developing other
types of malignancy in patients with MPN.9,10 In particular,
the risk of also developing LM is significantly increased
compared with the risk in a sex- and age-matched back-
ground population. 
Dual diagnoses of MPN and LM in the same patient
have previously been described in both individual case
reports and in small case series.11 However, a more sub-
stantial, population-based evaluation of this phenome-
non, together with a biorepository of tumor specimens
from such patients, has not yet been reported. The aim
of our study was to identify and characterize a nation-
wide cohort of Danish patients with dual diagnoses of
myeloproliferative and lymphoproliferative malignan-
cies. We describe what we believe to be the largest series
of patients with diagnoses of both MPN and LM, with
particular emphasis on the establishment of the cohort,
the histopathological classification of the malignancies,
and description of the clinical characteristics of the
patients.
Methods
Cohort identification
Patients diagnosed with both MPN and LM within the period
1977-2015 were identified through the national Danish Pathology
Registry (DPR).12 The DPR is a nationwide register that records
data on all pathology specimens from patients in Denmark. The
registry and its associated database are updated daily. Since essen-
tially all pathology investigations in Denmark are performed with-
in the tax-funded public health system, the coverage of the DPR is
close to 100%. The registry includes detailed variables related to
patients, specimens and workload. All Danish citizens and resi-
dents are assigned a unique identifier, the civil personal registra-
tion number, at birth or immigration.13 Using this registration
number, a patient’s data in the DPR can be linked to the many
other Danish clinical databases. In addition, each specimen identi-
fied via the DPR can be linked to the available formalin-fixed,
paraffin-embedded tissue biopsies stored in the diagnostic
archives of the Danish pathology departments, allowing identifi-
cation, location and retrieval of relevant primary diagnostic tissue
specimens from the cohort patients. 
The MPN diagnoses include PV, ET, PMF, CML, and MPN-U. In
order to exclude secondary myelodysplasias/MPN occurring as a
result of previous treatment for LM, only patients diagnosed with
either both diseases concomitantly (i.e., diagnosed no more than 6
months apart) or with MPN first and LM subsequently, were
selected for further histopathological revision. Because of the low
number of samples available for the period 1977 to 1990 and the
poor tissue quality of the older samples, only specimens from
patients diagnosed in 1990 or later were included in the final
cohort.
The study was approved by The Central Denmark Region
Committees on Health Research Ethics (record n.  1-10-72-161-15)
and the Danish Data Protection Agency (record n. 1-16-02-420-
15), and it was conducted in compliance with the principles of the
Helsinki Declaration. 
Data sources
All data sources were linked using the unique patient-specific
civil personal registration number. Clinical data were obtained
from the population-based Danish National Lymphoma Registry
(LYFO)14 and supplemented by medical records.
For comparison of overall survival, a diffuse large B-cell lym-
phoma (DLBCL) reference cohort matched for age, sex, and the
International Prognostic Index (IPI) was identified and randomly
selected from LYFO (n=100). For AITL patients, a reference cohort
previously described by Pedersen et al. was used (n=25).15
Tissue collection and histological revision
All specimens were pre-therapeutic biopsies from patients diag-
nosed with both MPN and LM. Formalin-fixed, paraffin-embed-
ded tissue specimens were collected from the archives at 15 differ-
ent Danish pathology departments. After careful evaluation of the
original pathology reports, new hematoxylin and eosin-stained
sections were cut from the study paraffin blocks and the
histopathological diagnoses were reviewed. If necessary, supple-
mentary immunohistochemical stains were assessed, in addition
to those originally performed. Samples were reviewed by an expe-
rienced hematopathologist (TLP) at a tertiary referral center
according to the 2017 revision of the 2008 World Health
Organization Classification of Tumours of Haematopoietic and
Lymphoid Tissues.8 AITL tumors were specifically tested for well-
known recurrent mutations in IDH2, TET2, DNMT3A, and RHOA
genes.
Statistical methods
Outcomes were described by overall survival, defined as the
time interval from LM diagnosis to last follow-up or death from
any cause. Overall survival estimates were calculated according to
the Kaplan-Meier method and compared using the log-rank test.
All statistical analyses were performed using STATA version IC
14.1 (StataCorp, College Station, TX, USA).
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Results
Establishment of the cohort
The algorithm leading to the establishment of the
cohort is shown in Figure 1. In total, 26,736 patients with
MPN were identified. Of these, 1,524 had an additional
registered diagnosis of concomitant or subsequent LM. If
multiple biopsies from the MPN and/or LM diagnosis of
a given patient were taken at different times the patient
would end up with multiple registrations in the DPR.
These redundant registrations were omitted (n=925).
Patients with diagnoses of MPN and/or LM, which were
unconfirmed after histopathological review (n=344),
were excluded. A group of 67 patients diagnosed with
LM prior to the MPN were also excluded, as were 18
patients diagnosed before 1990. Thus, diagnostic tissue
specimens from 170 patients were retrieved for
histopathological validation. Of these, 97 patients were
confirmed to have both MPN and LM and represent the
final cohort of the study.
Demographic and clinico-pathological features
Table 1 summarizes the demographic characteristics of
the patients. No major differences in sex distribution were
observed, either overall or at subtype-specific level. The
age at MPN diagnosis was for most patients within the
sixth and seventh decades of life with the exception of
patients with lymphoblastic lymphoma (LBL), who were
significantly younger (median 33 years; interquartile
range, 22-57 years). The overall average time between the
diagnoses of MPN and LM was 1.5 years and in the major-
ity of the patients (90%) both diagnoses were established
within 5 years of each other.
Table 2 shows a cross tabulation between MPN and LM
diagnoses. The most frequent LM diagnoses were chronic
lymphocytic leukemia (CLL, 32%) and DLBCL (21%), in
line with these being two of the more common LM enti-
ties in the general population. 
Peripheral T-cell lymphomas (PTCL) usually account for
approximately 10% of all lymphomas, which is in line
with the relative frequencies seen in our study.
J.M. Holst et al.
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Figure 1. Flowchart illustrating the establishment of the cohort. DPR: the Danish pathology register; MPN: myeloproliferative neoplasms; LM: lymphoproliferative
malignancy.
Interestingly, AITL patients accounted for 89% (8 out of 9)
of the MPN-associated PTCL, an unexpectedly high fre-
quency (5- to 7-fold) for this specific entity. AITL tumors
frequently harbored mutations of TET2 (60%), IDH2
(60%), DNMT3A (60%), and RHOA (80%) genes. All five
patients with LBL (B-cell lineage, n=2; T-cell lineage, n=2;
and unclassifiable, n=1) were associated with a pre-exist-
ing CML, probably being cases of lymphoid blast crises on
a CML background. 
Overall, 64% (n=62) of the MPN patients were diag-
nosed with a concurrent LM, while the remaining 36%
(n=35) developed LM subsequently. Figure 2 illustrates the
chronological occurrence of MPN and LM in each patient
with PTCL, DLBCL, and CLL. The majority (n=23; 77%)
of CLL patients were diagnosed with both malignancies
concurrently. In contrast, most DLBCL (n=11; 55%) and,
even more strikingly, most PTCL patients (n=6; 67%)
were diagnosed at a mean time interval of between 1 to 3
years after the MPN diagnosis (1.5 years for DLBCL and
2.8 years for PTCL). 
Outcome in selected lymphoma subtypes
In a survival analysis, patients with both MPN and
DLBCL had an inferior outcome compared with an age-,
sex-, and IPI-matched DLBCL reference cohort [hazard
ratio (HR)=1.9, 95% confidence interval (95% CI): 1.1-3.3;
P<0.02] (Figure 3A). The 5-year overall survival rate of the
patients with MPN+DLBCL was 19% (95% CI: 5-39%) as
compared with 34% (95% CI: 24-43%) for the DLBCL
patients of the matched reference cohort. 
In contrast, no difference was found in outcomes
between patients with both MPN and PTCL and patients
with ‘AITL only’ (Figure 3B). 
The 5-year overall survival of the patients with
MPN+CLL was 65% (95% CI: 45-79%). Historical data
from the Danish CLL group showed a corresponding
value for ‘CLL only’ patients diagnosed in the period 2012-
2017 of 79% (95% CI: 77-81%).16
Discussion
In establishing this population-based cohort, we identi-
fied a substantial number of patients diagnosed with
myeloid malignancies, who were also diagnosed, either at
the same time or later, with a lymphoid neoplasia. Among
these lymphoid neoplasias, AITL were found at a much
higher frequency than expected. We believe that this rep-
resents the largest reported cohort of patients with dual
MPN and LM diagnoses, and that the associated biorepos-
itory is unique for its potential to foster the recognition of
driver pathogenetic aberrations as well as the hierarchical
Myeloid and lymphoid neoplasms in the same patient
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Table 1. Demographic features of the study population. 
                                                                              All                        CLL                     DLBCL                     PTCL                     WM                     LBL
Number                                                                                97                               31                                20                                  9                               10                              5
Male/female ratio                                                              1.1                              0.9                               1.0                                0.8                             2.3                            4.0
Age, years                                                                                                                                                                                                                                                              
At MPN diagnosis, range                                             19-94                         57-88                          52-88                           60-82                        59-81                       19-57
At MPN diagnosis, median                                            71                               72                                71                                 67                              71                             33
At MPN diagnosis, IQR                                                63-79                         63-81                          66-79                           64-73                        64-77                       22-57
Time between the MPN and
LM diagnoses (mean), years                                         1.5                              1.4                               2.4                                2.8                             1.4                            1.7
CLL: chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL: diffuse large B-cell lymphoma; PTCL: peripheral T-cell lymphoma; WM: Waldenström macroglobuline-
mia; MPN: myeloproliferative neoplasms; IQR: interquartile range; LBL: lymphoblastic lymphoma.
Table 2. Overview of the associated myeloproliferative and lymphoproliferative malignancies.
                                                                                          PV                    ET                      PMF                   CML                   MPN-U                  Total
Chronic lymphocytic leukemia                                                      8                           6                               2                              1                               14                             31
Diffuse large B-cell lymphoma                                                      8                           2                               2                              2                                6                              20
Low grade B-cell lymphoma - NOS                                              4                            -                               3                              -                                4                              11
Peripheral T-cell lymphoma
Anaplastic large cell lymphoma                                             -                            -                               1                              -                                 -                               1
Angioimmunoblastic T-cell lymphoma                                 2                           2                               1                              -                                3                               8
Waldenström macroglobulinemia                                                 -                            1                               4                              2                                3                              10
Lymphoblastic lymphoma                                                               -                            -                               -                              5                                -                               5
Marginal zone lymphoma                                                                -                            -                               1                              -                                4                               5
Hodgkin lymphoma                                                                           -                            1                               -                              1                                -                               2
Follicular lymphoma                                                                         -                            1                               -                              1                                -                               2
Mantle cell lymphoma                                                                      -                            -                               -                              -                                1                               1
Primary CNS lymphoma                                                                   -                            -                               -                              1                                -                               1
Total                                                                                                    22                         13                             14                            13                              35                             97
PV: polycythemia vera; ET: essential thrombocythemia; PMF: primary myelofibrosis; CML: chronic myeloid leukemia; MPN-U, myeloproliferative neoplasms – unclassifiable;
NOS: not otherwise specified; CNS: central nervous system..
relationship within the clonal evolution of hematologic
malignancies.
Epidemiological studies have revealed that patients with
MPN have an increased standardized risk of developing
LM.9,17–20 Recently, a Swedish population-based study con-
firmed an increased risk of second malignancies in MPN
patients with a hazard ratio of 2.6 (2.0-3.3) for developing
lymphoma.10 However, none of the published studies indi-
cated the frequency of different LM subtypes. Our data
revealed a diverse range of different lymphoma entities. In
the general population, AITL is, along with PTCL-NOS,
the most common PTCL, accounting for 20-35% of all
cases of PTCL in Caucasian populations.21,22 Notably, in
our cohort, eight of nine PTCL cases were of angioim-
munoblastic type, i.e., approximately 4-fold the expected
number.
AITL has a complex clinical picture and is often diag-
nosed at advanced stage.23 Histopathological examination
of AITL tissue usually shows a microenvironment of non-
malignant bystander cells, together with a minor popula-
tion of neoplastic follicular helper T cells (TFH), which
are believed to be the cell of origin of AITL.24 Recently,
molecular alterations unique to AITL and to PTCL of
TFH-origin have been described.4,25 Among the most fre-
quent genomic alterations are recurrent mutations of
RHOA5,26 and epigenetic modifier genes such as
DNMT3A, TET2, and IDH2.1,3,27,28 The latter are well-
known genetic lesions and were originally identified in
myeloid malignancies including myelodysplastic syn-
dromes and MPN. DNMT3A and TET2 mutations have
been predominantly found in progenitors prior to T-cell
and B-cell commitment, whereas RHOA and IDH2 muta-
J.M. Holst et al.
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Figure 2. Swimmer plots showing, for each patient, for three selected lymphoid diagnoses the chronological occurrence of the myeloproliferative and lymphopro-
liferative malignancies. Each bar represents one patient in the study. Dark gray parts of the bars represent the time between the diagnosis of the myeloproliferative
neoplasm and the lymphoma diagnosis. Light gray parts of the bars represent time with both diagnoses to death or last follow-up. PTCL: peripheral T-cell lymphoma;
DLBCL: diffuse large B-cell lymphoma; CLL: chronic lymphocytic leukemia/small lymphocytic lymphoma.
tions are usually found more downstream in cells that
have undergone lineage specification.29 TET2 and IDH2
mutations are mutually exclusive in myeloid malignan-
cies, but often co-exist in AITL.5,25,29 Interestingly, the
combination of TET2 deletion together with RHOA
mutation has been shown to lead to the development of
AITL in mice.30-32 In spite of an increasing number of anec-
dotal reports of MPN associated with the development of
a variety of LM, no definitive relationship between the
conditions has been established.33 However, the relatively
high frequency of mutations in epigenetic modifier genes,
found in both myeloid and lymphoid malignancies, could
suggest a possible pathogenetic relevance of these muta-
tions for the dual malignant transformation. Moreover,
they may represent evidence of shared pathogenetic
mechanisms related to hierarchical mutation steps occur-
ring as early events in the hematopoietic neoplastic
process.  
Development of second malignancies in MPN patients
may influence survival.34 Our study indicates that patients
with both MPN and DLBCL have a worse prognosis com-
pared with a reference cohort of patients with DLBCL
alone matched for age, sex, and IPI score. This observa-
tion cannot be readily explained, but may be due to
added morbidity as a consequence of multiple treatment
courses related to both the myeloid and lymphoid malig-
nancies and/or added deleterious genomic alterations at
both stem cell and committed lineage-specific cell level.
Myeloid and lymphoid neoplasms in the same patient
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Figure 3. Survival analyses.
Kaplan Meier estimates of
overall survival in (A) patients
with diffuse large B-cell lym-
phoma with and without a
previous diagnosis of a
myeloproliferative neoplasm
and (B) patients with periph-
eral T-cell lymphoma with and
without a previous diagnosis
of a myeloproliferative neo-
plasm. DLBCL: diffuse large
B-cell lymphoma; MPN_
myeloproliferative neoplasm;
PTCL: peripheral T-cell lym-
phoma; AITL: angioim-
munoblastic T-cell lymphoma.  
A
B
Conversely, no significant outcome difference was seen
between patients with both MPN and AITL and a refer-
ence cohort diagnosed with AITL alone. AITL is a rare
disease with a poor prognosis and with frequent relapses.
Hence, our outcome analysis was expectedly hampered
by the limited size of the compared cohorts, and addi-
tional studies are needed to verify this observation. 
Recently, an overrepresentation of B-cell lymphomas in
patients with PMF treated with JAK1/2 inhibitors has
been observed.35 None of the patients with myelofibrosis
in our cohort had received JAK inhibition therapy. 
Observational studies based on archival material have
inherent limitations regarding the completeness of avail-
able clinical information and the validity of the
histopathological diagnoses. Our study is a nationwide
collaboration between departments of pathology and
hematology in Denmark, one major aim being to provide
specimens and clinico-pathological data from a popula-
tion-based cohort of patients diagnosed with both a
myeloid and a lymphoid malignancy. Furthermore, all
cases underwent histopathological validation including a
diagnostic update according to the most recent revision of
the World Health Organization classification.17 A
biorepository of tissue specimens has been established
and DNA extracted for genomic analysis from both the
MPN and LM samples.
In conclusion, we describe here the frequency, demo-
graphics and epidemiology of the largest reported cohort
of patients diagnosed with both MPN and LM. Patients
with both MPN and DLBCL have poorer outcomes than
those with DLBCL only. AITL is the lymphoma entity
with by far the highest relative frequency of associated
MPN. We hypothesize that shared genomic abnormali-
ties may predispose to the combined or sequential devel-
opment of MPN and LM in the same host. To further
investigate this hypothesis, we have established a
biorepository of all available specimens from this nation-
wide cohort. This unique material will be an invaluable
resource for the performance of genomic studies to inves-
tigate the pathogenetic relationship between MPN and
LM with possible novel therapeutic implications. 
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